Dr. Chad E. Beyer, Senior Vice President of R&D, will present an overview of results from Promentis’ Phase 2A clinical trial at the 10th annual CNS Summit in Boca Raton Florida.
Completed 28-patient Phase 2A behavioral biomarker study shows significant improvements in impulse control and 120-patient Phase 2 multi-center study in trichotillomania is fully enrolled
Company has initiated Phase 2 monotherapy study in trichotillomania and prepares for a Phase 2 add-on therapy study in OCD Milwaukee, Wisconsin | January 17, […]
Dr. Chad Beyer to provide nonclinical and clinical findings of the company’s first-in-class, System xc– activator Milwaukee, WI – December 5, 2018 — Promentis Pharmaceuticals, Inc., a […]
Promentis plans to initiate monotherapy and add-on therapy studies in two neuropsychiatric disorders Milwaukee, Wisconsin | November 16, 2018 — Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical […]
Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023, a novel activator of System xc-, at the annual Society for Neuroscience meeting taking place November 3-7, 2018 in San Diego, California.
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023.
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders, today announced it has completed a third round of equity investment totaling $26,000,000.
Promentis Pharmaceuticals, Inc., a specialty pharmaceutical company developing novel compounds for schizophrenia, Parkinson's disease and pediatric disorders including autism, announced today it has raised nearly $3 million in Series B financing.
Promentis Pharmaceuticals, Inc. announced today that it has received a Phase II Small Business Innovation Research (SBIR) award from the National Institute of Mental Health (NlMH) of the National Institutes of Health. The three-year award, totaling $1.8 million, is the continuation of a Phase I SBIR grant received previously by Promentis to develop novel compounds to treat schizophrenia.